Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. Show more
Location: Rue Edouard Belin 12, Mont-Saint-Guibert, 1435, Belgium | Website: https://www.nyxoah.com | Industry: Medical Instruments & Supplies | Sector: Healthcare
Market Cap
220.8M
52 Wk Range
$5.55 - $11.87
Previous Close
$5.88
Open
$6.00
Volume
80,353
Day Range
$5.60 - $6.00
Enterprise Value
193.9M
Cash
42.99M
Avg Qtr Burn
-15.22M
Insider Ownership
41.73%
Institutional Own.
22.78%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|